11 March 2024
EMA/108999/2024
EMEA/H/C/004935

Public statement

Blenrep (belantamab mafodotin)

Non-renewal of the conditional marketing authorisation in the European Union

On 23 February 2024, the European Commission issued a decision to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) in the European Union (EU). The marketing authorisation holder for the medicine was GlaxoSmithKline (Ireland) Limited.

The non-renewal of the marketing authorisation follows the opinion issued by EMA's human medicines committee, CHMP, which recommended to not renew the authorisation because the benefits of Blenrep no longer outweigh its risks.

Further information is available in the news announcement published at the time of the CHMP opinion.

Blenrep was granted a conditional marketing authorisation valid throughout the EU on 25 August 2020 for the treatment of multiple myeloma.

The European Public Assessment Report (EPAR) for Blenrep has been updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union